Document is current
Any future updates will be listed below
-
Authors
Wallimann, Rahel H.
Mehta, Avni
Mapanao, Ana Katrina
Köster, Ulli
Kneuer, Rainer
Schindler, Patrick
van der Meulen, Nicholas P.
Schibli, Roger
Müller, Cristina https://orcid.org/0000-0001-9357-9688
-
Funding
Funding for this research was provided by:
PSI - Paul Scherrer Institute
- License Information
-
More Information
Article History
Received: 15 August 2024
Accepted: 2 December 2024
First Online: 16 December 2024
Declarations
:
: This study was performed in agreement with the national law and PSI-internal guidelines of radiation safety protection. In vivo experiments were approved by the local veterinarian department and ethics committee and conducted in accordance with the Swiss law of animal protection.
: The University Hospital Basel and the Paul Scherrer Institute have filed a patent with regard to [161Tb]Tb-DOTA-LM3. R. Schibli, N. van der Meulen and C. Müller are listed as co-inventors on the patent application. Merck & Cie, Schaffhausen and PSI have a patent with regard to albumin-binding folate radioconjugates. R. Schibli and C. Müller are listed as co-inventors on the patent application. R. H. Wallimann, R. Kneuer and P. Schindler are employed by Novartis, Basel, Switzerland.
